This review is intended as an educational resource for healthcare professionals. It discusses the updated International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) Subcommittee on Control of Anticoagulation guidance on the use of direct oral anticoagulants (DOACs) for the treatment and prevention of VTE in patients with obesity, and in those undergoing bariatric surgery.1 The new guidance is an update to the 2016 ISTH SSC published guidance and is based on newly published data on the use of DOACs in obese and severely obese patients.1,2 The guidance is an important resource for healthcare professionals managing anticoagulation in this group of patients. This publication has been commissioned by Bayer. The production of the content is entirely independent, but has been reviewed by Bayer for technical accuracy prior to publication.
Please login below to download this issue (PDF)